(C) 2009 Elsevier Inc. All rights reserved.”
“Many aspects of biodefense research require quantitative LY2109761 mouse growth assessments of the test agent. This study evaluated the BioNanoPore (BNP (TM)) technology to quantitate

Bacillus anthracis and Yersinia pestis faster than traditional plate counting methods. The BNP (TM) technology enabled quantification of B. anthracis and Y. pestis in phosphate-buffered saline and naive rabbit blood at 6 and 24 h, respectively. After 6 h of growth, counts for B. anthracis ranged from 6.19-6.45 log(10) CFU ml(-1) on BNP (TM), while counts after 24 h on tryptic soy agar (TSA) ranged from 6.51-6.58 log(10) CFU ml(-1). For Y. pestis, counts on BNP (TM) at 24 h ranged from 6.31-6.41 log(10) CFU ml(-1) on BNP (TM) and ranged from 6.44-6.89 log(10) CFU ml(-1) on TSA at 48 h.

This study demonstrates that the BNP (TM) technology provides a more CRT0066101 cost rapid detection of B. anthracis and Y. pestis, which could aid in the evaluation of potential medical countermeasures and treatments as well as other biological defense applications such as surface sampling or decontamination efficacy.”
“Protease-activated receptors (PARs) play important roles in the regulation of brain function such as neuro-inflammation by transmitting the signal from proteolytic enzymes such as thrombin and trypsin. We and others have reported that a member of the family, PAR-2 is activated by trypsin, whose involvement in the neurophysiological process is increasingly evident, and is involved in the neuroinflammatory processes including morphological changes of astrocytes.

In this study, we investigated the role of PAR-2 in the production of nitric oxide (NO) in rat primary astrocytes. Treatment of PAR-2 agonist trypsin increased NO production in a dose-dependent manner, which was mediated by the induction of inducible nitric-oxide synthase. The trypsin-mediated production of NO was mimicked by PAR-2 agonist peptide and reduced by either pharmacological PAR-2 antagonist peptide or by siRNA-mediated inhibition of PAR-2 expression, which suggests the critical role of PAR-2 in this click here process. NO production by PAR-2 was mimicked by PMA, a PKC activator, and was attenuated by Go6976, a protein kinase C (PKC) inhibitor. PAR-2 stimulation activated three subtypes of mitogen-activated protein kinases (MAPKs): extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK. NO production by PAR-2 was blocked by inhibition of ERK, p38, and JNK pathways. PAR-2 stimulation also activated nuclear factor-kappa B (NF-kappa B) DNA binding and transcriptional activity as well as I kappa B alpha phosphorylation. Inhibitors of NF-kappa B pathway inhibited PAR-2-mediated NO production. In addition, inhibitors of MAPK pathways prevented transcriptional activation of NF-kappa B reporter constructs.